Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 8/2017

01-08-2017 | Focussed Research Review

Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments

Authors: Sabina Sangaletti, Claudia Chiodoni, Claudio Tripodo, Mario P. Colombo

Published in: Cancer Immunology, Immunotherapy | Issue 8/2017

Login to get access

Abstract

The complex interaction between cells undergoing transformation and the various stromal and immunological cell components of the tumor microenvironment (TME) crucially influences cancer progression and diversification, as well as endowing clinical and prognostic significance. The immunosuppression characterizing the TME depends on the recruitment and activation of different cell types including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. Less considered is the non-cellular component of the TME. Here, we focus on the extracellular matrix (ECM) regulatory activities that, within the TME, actively contribute to many aspects of tumor progression, acting on both tumor and immune cells. Particularly, ECM-mediated regulation of tumor-associated immunosuppression occurs through the modulation of myeloid cell expansion, localization, and functional activities. Such regulation is not limited to the TME but occurs also within the bone marrow, wherein matricellular proteins contribute to the maintenance of specialized hematopoietic stem cell niches thereby regulating their homeostasis as well as the generation and expansion of myeloid cells under both physiological and pathological conditions. Highlighting the commonalities among ECM-myeloid cell interactions in bone marrow and TME, in this review we present a picture in which myeloid cells might sense and respond to ECM modifications, providing different ECM-myeloid cell interfaces that may be useful to define prognostic groups and to tailor therapeutic interventions.
Literature
2.
go back to reference Acerbi I, Cassereau L, Dean I et al (2015) Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 7:1120–1134. doi:10.1039/c5ib00040h CrossRef Acerbi I, Cassereau L, Dean I et al (2015) Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 7:1120–1134. doi:10.​1039/​c5ib00040h CrossRef
8.
27.
go back to reference Kaplan G (1983) In vitro differentiation of human monocytes. Monocytes cultured on glass are cytotoxic to tumor cells but monocytes cultured on collagen are not. J Exp Med 157:2061–2072CrossRefPubMed Kaplan G (1983) In vitro differentiation of human monocytes. Monocytes cultured on glass are cytotoxic to tumor cells but monocytes cultured on collagen are not. J Exp Med 157:2061–2072CrossRefPubMed
30.
go back to reference Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531. doi:10.1038/nri3024 CrossRefPubMed Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531. doi:10.​1038/​nri3024 CrossRefPubMed
37.
38.
go back to reference Tripodo C, Sangaletti S, Guarnotta C et al (2012) Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood 120:3541–3554. doi:10.1182/blood-2011-12-398537 CrossRefPubMed Tripodo C, Sangaletti S, Guarnotta C et al (2012) Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood 120:3541–3554. doi:10.​1182/​blood-2011-12-398537 CrossRefPubMed
42.
go back to reference Pellagatti A, Cazzola M, Giagounidis A et al (2007) Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes. Leuk Res 31:S35-S. doi:10.1016/S0145-2126(07)70061-9 CrossRef Pellagatti A, Cazzola M, Giagounidis A et al (2007) Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes. Leuk Res 31:S35-S. doi:10.​1016/​S0145-2126(07)70061-9 CrossRef
48.
go back to reference Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J (2012) Interactions between cancer stem cells and their niche govern metastatic colonization. Cancer Res 72(Suppl):SY28-02. doi:10.1158/1538-7445.Am2012-Sy28-02 Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J (2012) Interactions between cancer stem cells and their niche govern metastatic colonization. Cancer Res 72(Suppl):SY28-02. doi:10.1158/1538-7445.Am2012-Sy28-02
50.
go back to reference Condamine T, Dominguez GA, Youn JI, et al (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Science Immunol 1:aaf8943. doi:10.1126/sciimmunol.aaf8943 Condamine T, Dominguez GA, Youn JI, et al (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Science Immunol 1:aaf8943. doi:10.​1126/​sciimmunol.​aaf8943
Metadata
Title
Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments
Authors
Sabina Sangaletti
Claudia Chiodoni
Claudio Tripodo
Mario P. Colombo
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 8/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-2014-y

Other articles of this Issue 8/2017

Cancer Immunology, Immunotherapy 8/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine